Zip6 Transporter Is an Essential Component of the Lymphocyte Activation Machinery.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
15 01 2019
Historique:
received: 14 05 2018
accepted: 13 11 2018
pubmed: 16 12 2018
medline: 29 10 2019
entrez: 16 12 2018
Statut: ppublish

Résumé

Zinc deficiency causes immune dysfunction. In T lymphocytes, hypozincemia promotes thymus atrophy, polarization imbalance, and altered cytokine production. Zinc supplementation is commonly used to boost immune function to prevent infectious diseases in at-risk populations. However, the molecular players involved in zinc homeostasis in lymphocytes are poorly understood. In this paper, we wanted to determine the identity of the transporter responsible for zinc entry into lymphocytes. First, in human Jurkat cells, we characterized the effect of zinc on proliferation and activation and found that zinc supplementation enhances activation when T lymphocytes are stimulated using anti-CD3/anti-CD28 Abs. We show that zinc entry depends on specific pathways to correctly tune the NFAT, NF-κB, and AP-1 activation cascades. Second, we used various human and murine models to characterize the zinc transporter family, Zip, during T cell activation and found that Zip6 was strongly upregulated early during activation. Therefore, we generated a Jurkat Zip6 knockout (KO) line to study how the absence of this transporter affects lymphocyte physiology. We found that although Zip6KO cells showed no altered zinc transport or proliferation under basal conditions, under activation, these KO cells showed deficient zinc transport and a drastically impaired activation program. Our work shows that zinc entry into activated lymphocytes depends on Zip6 and that this transporter is essential for the correct function of the cellular activation machinery.

Identifiants

pubmed: 30552163
pii: jimmunol.1800689
doi: 10.4049/jimmunol.1800689
doi:

Substances chimiques

Cation Transport Proteins 0
Cytokines 0
NF-kappa B 0
NFATC Transcription Factors 0
Neoplasm Proteins 0
SLC39A6 protein, human 0
Transcription Factor AP-1 0
Zinc J41CSQ7QDS

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

441-450

Informations de copyright

Copyright © 2019 by The American Association of Immunologists, Inc.

Auteurs

Natalia Colomar-Carando (N)

Laboratory of Molecular Physiology, Department of Experimental and Health Sciences, Pompeu Fabra University, 08003 Barcelona, Spain.

Alberto Meseguer (A)

Laboratory of Molecular Physiology, Department of Experimental and Health Sciences, Pompeu Fabra University, 08003 Barcelona, Spain.

Iván Company-Garrido (I)

Laboratory of Molecular Physiology, Department of Experimental and Health Sciences, Pompeu Fabra University, 08003 Barcelona, Spain.

Sabrina Jutz (S)

Division of Immune Receptors and T Cell Activation, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria.

Víctor Herrera-Fernández (V)

Laboratory of Molecular Physiology, Department of Experimental and Health Sciences, Pompeu Fabra University, 08003 Barcelona, Spain.

Alex Olvera (A)

HIVACAT, IrsiCaixa AIDS Research Institute, Germans Trias i Pujol University Hospital, 08916 Badalona, Spain.
University of Vic and Central Catalonia, 08500 Vic, Spain; and.

Kerstin Kiefer (K)

Laboratory of Molecular Physiology, Department of Experimental and Health Sciences, Pompeu Fabra University, 08003 Barcelona, Spain.

Christian Brander (C)

HIVACAT, IrsiCaixa AIDS Research Institute, Germans Trias i Pujol University Hospital, 08916 Badalona, Spain.
University of Vic and Central Catalonia, 08500 Vic, Spain; and.
Institució Catalana de Recerca i Estudis Avançats, 08010 Barcelona, Spain.

Peter Steinberger (P)

Division of Immune Receptors and T Cell Activation, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria.

Rubén Vicente (R)

Laboratory of Molecular Physiology, Department of Experimental and Health Sciences, Pompeu Fabra University, 08003 Barcelona, Spain; ruben.vicente@upf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH